# A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

> **NCT02425891** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 902 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02425891
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2020-04-14
- **Final completion:** 2021-08-31
- **Target enrollment:** 902 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425891, "A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02425891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*